Abstract 1688P
Background
Elderly patients are disproportionately burdened with cancer morbidity and mortality. The disease and its treatment are complicated by ageing-related issues such as loss of loved ones, socioeconomic changes, and the presence of comorbidities. Thus, they are at high risk of psychosocial distress and poor health-related quality of life. There is a significant paucity of data on the prevalence and determinants of psychosocial distress among elderly patients with cancer in Nigeria, necessitating this study.
Methods
This descriptive cross-sectional study was conducted among 296 patients aged 60 years and older with cancer attending the NSIA LUTH Cancer Centre. Data collection was interviewer-based using a structured questionnaire along with the Depression, Anxiety, and Stress Scale 21-item (DASS-21) and Functional Assessment of Chronic Illness Therapy—Spiritual Well-Being 12 (FACITsp-12). The association between different variables was assessed by chi square. Statistical analysis was done with IBM Statistical Package for Social Sciences Version 25, and a p value of <0.05 was regarded as significant.
Results
The prevalence of psychosocial distress among the respondents was depression (19.9%), anxiety (46.0%), and stress (3.0%). The majority of the respondents (77.7%) had intermediate/high spiritual levels. The prevalence of depression was significantly higher in those with comorbidities and those receiving chemotherapy. A high spiritual level was also significantly associated with a lower level of depression, anxiety, and stress.
Conclusions
We found a higher prevalence of psychosocial distress among patients who received chemotherapy as part of their treatment and also among those with comorbidities. A higher spiritual level was found to be associated with a reduced level of psychosocial distress. Therefore, there is a need to screen patients with comorbidities and those on chemotherapy for psychosocial distress in order to identify those in need of additional psychological and social work support. A holistic approach that integrates psychosocial and spiritual care into cancer treatment not only alleviates the emotional burden but also contributes to improved overall well-being and treatment outcomes.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Z. A. Ogunjimi.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1699P - Impact of Latino ethnicity on the gut microbiome and response to immune checkpoint inhibition (ICI) with CBM588 in patients (pts) with metastatic renal cell cancer (mRCC)
Presenter: Regina Barragan-Carrillo
Session: Poster session 11
1700P - Impact of sarcomatoid (S) and rhabdoid (R) components (comp.) on the efficacy of nivolumab (N) +/- ipilimumab (I) in the first-line (L1) treatment of metastatic clear cell renal cell carcinoma (mRCC) in the randomized phase II BIONIKK trial
Presenter: Yann-Alexandre Vano
Session: Poster session 11
1701P - NEOTAX: A phase II trial of neoadjuvant toripalimab plus axitinib for clear cell renal cell carcinoma with inferior vena cava tumor thrombus
Presenter: Liangyou Gu
Session: Poster session 11
1702P - Updated results of phase II study of cabozantinib (Cabo) with nivolumab (Nivo) and ipilimumab (Ipi) in advanced renal cell carcinoma with divergent histologies (RCCdh)
Presenter: Bradley McGregor
Session: Poster session 11
1703P - Updated overall survival in patients with prior checkpoint inhibitor (CPI) therapy in the phase III TIVO-3 study
Presenter: Miguel Zugman
Session: Poster session 11
1704P - Potential surrogate endpoints for overall survival (OS) in immunotherapy (IO)-treated metastatic renal cell carcinoma (mRCC): An International Metastatic Database Consortium (IMDC) study
Presenter: Renee Saliby
Session: Poster session 11
1705P - Association between baseline radiological tumor burden (BRTB) and outcomes in metastatic clear cell renal cell carcinoma (mccRCC) treated with first line (1L) immunotherapy (IO)-based regimens
Presenter: Rashad Nawfal
Session: Poster session 11
1707P - A plasma proteomic based algorithm is associated with prognosis in renal cell carcinoma
Presenter: Eddy Saad
Session: Poster session 11
1708P - The clinical value of tumor-informed minimal residual disease detection in renal cell carcinoma
Presenter: linhui wang
Session: Poster session 11